Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/07/26	US$1.150	+0.88%	72,401
07/07/26	US$1.140	-1.72%	87,378
06/07/26	US$1.160	0.00%	71,520
02/07/26	US$1.160	+3.57%	378,014
01/07/26	US$1.120	-6.67%	2,335,682

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.140USD

Average target price

25.00USD

Spread / Average Target

+2,092.98%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 08/07/2026 BST			5-day change	1st Jan Change
1.150 ^USD	+0.88%		-4.17%	-36.81%

04-07	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
03-26	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI

Market Cap	4.34M 3.8M 3.5M 3.24M 6.15M 414M 6.26M 42M 16.35M 203M 16.29M 15.93M 705M	P/E 2026 *	-0.44x	P/E 2027 *	-0.44x
Enterprise Value	4.34M 3.8M 3.5M 3.24M 6.15M 414M 6.26M 42M 16.35M 203M 16.29M 15.93M 705M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	99.47%	Yield 2026 *	-	Yield 2027 *	-

04-07	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
03-26	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
03-16	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
03-16	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
03-11	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
03-06	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE
12-09	Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025	CI
11-19	Alzamend Neuro, Inc. Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 Lithium in Brain Study Conducted at Massachusetts General Hospital	CI
11-19	Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital	RE
11-18	Alzamend Neuro, Inc. Announces the Passing of Andrew H. Woo, M.D., Ph.D., Board Director on November 14, 2025	CI
08/10/25	Alzamend Neuro Insider Sold Shares Worth $344,222, According to a Recent SEC Filing	MT
10/09/25	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2025	CI
22/07/25	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2025	CI

12/04/23	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
27/12/21	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
01/10/21	ALZAMEND NEURO : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

Alzamend Neuro, Inc. Share Price

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation: Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news : Alzamend Neuro, Inc.

Analysts' recommendations: Alzamend Neuro, Inc.

Press Releases: Alzamend Neuro, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

04-07	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
03-26	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR
03-16	Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	PR
11-19	Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital	PR
28/07/25	Alzamend Neuro to Present at the 2025 Military Health System Research Symposium	AQ

1 day	+0.88%
1 week	-4.17%
Current month	-4.17%
1 month	+3.60%
3 months	+24.11%
6 months	-50.85%
Current year	-36.81%

1 week	1.06	1.19
1 month	1.06	1.37
Current year	0.84	2.54
1 year	0.84	3.6
3 years	0.84	729
5 years	0.84	11,178
10 years	0.84	45,292.48

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	19/11/2018
David Katzoff DFI	Director of Finance/CFO	64	04/08/2022
Henry Nisser LAW	General Counsel	57	30/04/2019

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	25/02/2016
William Horne CHM	Chairman	57	31/05/2021
Stephan Jackman BRD	Director/Board Member	50	31/08/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
04-13	HYPERSCALE DATA, INC.	Buy	Company	108,388	13.5324%
04-13	Todd Ault	Other	Founder	0	0%
12-22	Todd Ault	Sell	Founder	1,851	0.2311%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	+0.88%	-4.17%	-60.07%	-99.83%	4.34M
LONZA GROUP AG	-0.24%	+4.98%	+2.69%	+9.14%	49.74B
REVOLUTION MEDICINES, INC.	-0.36%	+1.33%	+417.51%	+619.10%	40.49B
BEONE MEDICINES AG	-2.29%	+5.93%	+25.27%	+59.26%	34.35B
IQVIA HOLDINGS INC.	-2.13%	+5.47%	+25.45%	-6.01%	34.75B
CELLTRION, INC.	-0.79%	+2.02%	+3.83%	+36.42%	26.98B
ASCENDIS PHARMA A/S	+3.82%	+3.92%	-	-	16.58B
MEDPACE HOLDINGS, INC.	-2.62%	+0.45%	+66.82%	+125.87%	15.6B
IONIS PHARMACEUTICALS, INC.	-2.17%	+6.52%	+102.15%	+102.15%	14.27B
EUROFINS SCIENTIFIC SE	-2.70%	-2.19%	+11.25%	+18.19%	13.76B
Average	-0.86%	+3.09%	+66.10%	+96.03%	24.65B
Weighted average by Cap.	-1.00%	+4.37%	+93.71%	+139.17%

	2026 *	2027 *
Net sales	-	-
Net income	-8.5M -7.45M -6.86M -6.35M -12.05M -812M -12.27M -82.31M -32.05M -398M -31.92M -31.22M -1.38B	-10.8M -9.46M -8.72M -8.07M -15.3M -1.03B -15.59M -105M -40.72M -506M -40.55M -39.67M -1.76B
Net Debt	-	-